This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Carboplatin concentrate for solution for infusion
  • /
  • Prostate Cancer Intensive, Non-Cross Reactive Ther...
Clinical trial

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Read time: 1 mins
Last updated:1st Oct 2016
Identifier: NCT02903160

The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer. The hypothesis is that the identification of optimal combinations and sequencing of therapies can help prevent or delay the development of therapeutic drug resistance, and can be safely tolerated.


Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate Cancer

 

Category Value
Date last updated at source 2016-09-12
Study type(s) Randomised clinical trial
Expected enrolment 40
Study start date 2016-10-01
Estimated primary completion date 2019-10-01

View full details